BeyondSpring (NASDAQ:BYSI) Trading Down 4.2% – Time to Sell?

Posted by Patrick Bannon on Dec 26th, 2025

BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report) was down 4.2% during trading on Friday . The company traded as low as $1.81 and last traded at $1.84. Approximately 69,525 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 716,864 shares. The stock had previously closed at $1.92.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a report on Monday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

View Our Latest Stock Analysis on BYSI

BeyondSpring Price Performance

The stock has a market cap of $74.21 million, a PE ratio of -12.27 and a beta of 0.53. The stock’s fifty day moving average is $1.98 and its 200-day moving average is $2.03.

Institutional Trading of BeyondSpring

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC boosted its holdings in BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 951.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 256,212 shares of the company’s stock after acquiring an additional 231,844 shares during the period. Geode Capital Management LLC owned 0.64% of BeyondSpring worth $603,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 40.29% of the company’s stock.

About BeyondSpring

(Get Free Report)

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.